Ocrelizumab versus fingolimod after natalizumab cessation in multiple sclerosis: an observational study.
Kévin BigautLaurent KremerThibaut FabacherGuido AhleMathilde GoudotMarie FleuryClaude GaultierSylvie CourtoisNicolas CollonguesJérôme de SezePublished in: Journal of neurology (2022)
Our results suggest ocrelizumab is potentially a better exit strategy than fingolimod after natalizumab cessation.
Keyphrases